Drug Profile
Research programme: sclerostin antibodies - Amgen/UCB
Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator Amgen; UCB
- Class Antibodies
- Mechanism of Action SOST protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Bone resorption
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Bone-resorption in USA (Parenteral)
- 05 Jul 2011 Preclinical trials in Bone resorption in USA (Parenteral)